Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

176.19 +0.02 (+0.01%)
Official Closing Price Updated: 7:00 PM EST, Dec 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AbbVie

< Previous 1 2 3 4 5 6 7 8 Next >
AbbVie Inc. (NYSE: ABBV) Highlighted for Surprising Price Action
Via Investor Brand Network
High-yield, deep-value AbbVie fell off the patent cliff and lived
AbbVie's deep value and high yield attract income investors, and the patent cliff worry lessens daily. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
AbbVie Inc. (NYSE: ABBV) Highlighted for Surprising Price Action
Via Investor Brand Network
AbbVie Inc. (NYSE: ABBV) Making Surprising Moves in Monday Session
Via Investor Brand Network
Clorox Pullback Presents a Chance to Clean Up on a 3.6% Dividend
The Clorox Company's 44% two-year plunge has created an opportunity to own a defensive stock with a shiny 3.6% dividend. 
Via MarketBeat
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
Flee to Healthcare Stocks if Recession Rears its Head?
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
Exposures Economy Product Safety
High Yield, Low Beta Stocks to Buy for the Next Market Meltdown
The market is set up for a fall, and it may start soon, as soon as the CPI data is released. These low-beta stocks are poised to outperform and pay dividends 
Via MarketBeat
Topics Economy Stocks
Exposures Economy Interest Rates US Equities
Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
Data readout expected in Q4 2024 
From Alector, Inc.
Via GlobeNewswire
A Significant Reversal is in Sight for These 5 Med Tech Companies
Med tech stocks are down YOY despite strong secular tailwinds, cash flow, and dividends; the downturn in action is an opportunity and reversal is at hand. 
Via MarketBeat
5 Best Stocks to Buy in a Bear Market
Want income-producing assets and stable stocks? Look for stocks with stable cash flow in rock-solid industries for the best stocks to buy in a bear market. 
Via MarketBeat
Topics Economy
Exposures Economy
3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Robust pipelines make these three pharmaceutical stocks solid choices for investors looking for stocks to buy and hold for long-term gains 
Via MarketBeat
Exposures COVID-19
Is Growth Priced into Amgen Stock after Earnings Beat?
Amgen earnings delivered a solid earnings report after the market closed but analyst sentiment suggests that growth may already be priced into AMGN stock. 
Via MarketBeat
The Patent Cliff Is Why AbbVie Is Moving Higher
High-yielding AbbVie will retest the all-time high after posting a solid quarter underpinned by new treatments and relative strength in Humira. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
3 Dividend Stocks That Still Make Sense in 2023
Investors are still faced with an uncertain market which is favorable for these three dividend stocks regardless of what happens in the economy 
Via MarketBeat
Topics Economy
Exposures Economy
High-Yield Pfizer Falls Off The COVID Cliff, And Survives
Pfizer is a value and high-yield compared to its peers and it it outperforming expectations in 2023; The pipeline is robust. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Hagens Berman: Class Action Accuses AbbVie Inc. of Unfair Pricing of Autoimmune Drug Humira Following 470% Cost Increase
From Hagens Berman Sobol Shapiro LLP
Via Business Wire
Why Next Week's Earnings Report is Good for Johnson & Johnson
Investors have had to digest some negative news headlines, but if you look past that a dividend king like JNJ can be a boring but reliable buy in this market 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
BioNTech Is Ripe For A Rebound In 2023
BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
These 3 Dividend Growers Yield More Than the 10-Year Note
Dividend aristocrats with yields greater than the 10-year note yield plus the potential for price appreciation could be a winning formula in this environment. 
Via MarketBeat
Topics Bonds
Exposures Debt Markets
Healthcare Stocks With at Least 30 Years of Dividend Increases
Among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield. 
Via MarketBeat
Diversify Your Income with These 2 High-Yielding Dividend ETFs
Diversification is a term widely used when it comes to investing in the stock market. It means spreading your investment across different sectors and indust 
Via MarketBeat
Topics ETFs
How to Pick the Best Dividend Stocks
A stock’s dividend yield is a key metric for investors, so what is a good dividend yield? We’ll explore the answer in this article. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
The Stock That Tripled in a Day...And May Not Be Done
Reata Pharmaceuticals now has a long-coveted commercialized drug in its portfolio. Should investors covet this biotech stock for their portfolios? 
Via MarketBeat
Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor
Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. The company reported its first revenue for Botox competitor Daxxify. 
Via MarketBeat
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. 
Via MarketBeat
Johnson & Johnson: Taking The Bull By The Horns?
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. 
Via MarketBeat
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
MarketBeat Week in Review – 2/13 - 2/17
Retail sales were up but so was inflation which meant more volatility for stocks. Enjoy your holiday weekend and catch up on our most read stories this week 
Via MarketBeat
Topics Economy
Exposures Interest Rates
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.